The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic
center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic
strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic
syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant
Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area;
Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized
Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver;
and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an
important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and
promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and
Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease
and we define targets for prevention/treatment that could transform clinical practice.
Specific Aims of the Hepatobiology and Toxicology COBRE are to:
1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build
and sustain the overall research infrastructure at UofL.
2. Expand and strengthen the multidisciplinary program in research education, mentoring and career
development in Hepatobiology and Toxicology, and systematically track and evaluate the progress.
3. Provide the necessary research resources and translational science/basic technologies to support state-of-
the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program.
4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver
diseases/toxicant exposures and communicate our findings to the public.
In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of
a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to
compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our
investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new
renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75
million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success,
extends and strengthens the scope of the program, and provides a roadmap for sustainability.
Public Health Relevance Statement
The University of Louisville (UofL) Hepatobiology and Toxicology COBRE is a unique thematic research
center. We have strengthened UofL’s biomedical research infrastructure through the establishment of a
thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to
compete for independent funding. This Phase II proposal builds on our Phase I success and extends and
strengthens the scope of the program.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Acute Liver FailureAddressAdultAffectAlcoholic Liver DiseasesAmericanAreaBiomedical ResearchCenters of Research ExcellenceChildCirrhosisCollaborationsCommunicationCommunitiesComplexCore FacilityData AnalysesDevelopmentDiabetes MellitusDisciplineDrug InteractionsDrug abuseEnsureEnvironmentEnzymesFDA approvedFosteringFundingGoalsGrantHealthHepatitis AHepatitis BHepatitis CHomeHomelessnessIndustrializationIndustryInjuryInternationalKentuckyLaboratoriesLinkLiverLiver FailureLiver diseasesMarketingMentorsMetabolic syndromeMetabolismMolecular TargetMorbidity - disease rateNational Institute on Alcohol Abuse and AlcoholismObesityOrganOverweightPharmaceutical PreparationsPharmacotherapyPhasePhase I Clinical TrialsPreventionPrimary carcinoma of the liver cellsProcessProgram SustainabilityPublicationsResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResourcesScientistStructureTechnologyTherapeuticToxic Environmental SubstancesToxicant exposureToxicologyTranslational ResearchUnited States National Institutes of HealthUniversitiesUniversity resourcesbiobankcareer developmentclinical practicedrug induced liver injuryeducation researchexperienceliver injuryliver transplantationmembermultidisciplinarynon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeuticsnutritionpersonalized medicinepreventprogramsrecruitsuccesstoxicantviral liver disease
No Sub Projects information available for 5P20GM113226-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P20GM113226-09
Patents
No Patents information available for 5P20GM113226-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P20GM113226-09
Clinical Studies
No Clinical Studies information available for 5P20GM113226-09
News and More
Related News Releases
No news release information available for 5P20GM113226-09
History
No Historical information available for 5P20GM113226-09
Similar Projects
No Similar Projects information available for 5P20GM113226-09